

Investor Presentation

Q2FY27

27-10-2026

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum




	Revenue	EBITDA	PAT
Q2FY27	INR 7,404 Cr	INR 1,388 Cr ⌈ 18.7% Margin ⌋	INR 878 Cr ⌈ 11.9% Margin ⌋

Business Performance Snapshot

	One India	North America	One Africa	Emerging Markets & Europe
Q2FY27	INR 3,516 Cr ▲ 12% (YoY)	\$ 172 Mn	\$ 123 Mn	\$ 101 Mn
	Highest-ever quarterly revenue	Received U.S. FDA approval for gAdvair Diskus	SA private growing 1.3x faster than the market ¹	Resilient performance amid geopolitical uncertainties

1. Market data as per IQVIA MAT Aug'26

Revenues INR 7,404 Cr



EBITDA 1,388 Cr

Q2FY27 (Consolidated)		
	Q2FY27 (INR Cr)	Q2FY26 (INR Cr)
Total Revenue from Operations	7,404	7,589
EBITDA	1,388	1,895
EBITDA %	18.7%	25.0%
PAT	878	1,351
PAT %	11.9%	17.8%

R&D² INR 423 Cr | 5.7% of revenue

1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

Highest-ever quarterly revenue of INR 3,516 Cr



Branded Prescription

- ❖ Cipla maintained #2 rank in overall chronic segment²
- ❖ Continued portfolio expansion with recent launch of Yurpeak, Duolin Syncrobreathe, Revesmart and Rizontem
- ❖ Double-digit growth² in chronic therapies like Respiratory, Cardiac, Urology, Anti-diabetes, and Dermatology



Trade Generics


- ❖ Delivered a strong double-digit QoQ growth
- ❖ 3 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr
- ❖ 18 new launches in Q2FY27



Consumer Health

- ❖ Anchor and transitioned brands continuing to grow bigger
- ❖ Haircare delivered strong double-digit growth
- ❖ Omnigel, Nicotex, Prolyte and Cipladine maintained their leadership positions in the market

India Rx : Strengthening Our Journey with Strategic Therapeutic Focus



Largest pharma company by volume (units) in market²

Our in-house brand franchise, Dyltor², has scaled to over INR 800 Cr+

Respiratory supremacy, with Cipla's brand franchises occupying all top 5 spots²

Key Market Highlights

1000+ Cr Foracort

Biggest Respiratory Brand in IPM²

23 Brands

IPM² Brands in Top 300 ranks

36 Brands

IPM² Brands with revenue > INR 100 Cr

7 Therapies

With IPM² Top 5 ranks

1. Market data as per IQVIA YTD Sep'26 | 2. Market data as per IQVIA MAT Sep'26

Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies



Respiratory



India's first once-daily nebulized bronchodilator for management of chronic obstructive pulmonary disease

Diabetology



Galvus DM [Vildagliptin SR+ Dapagliflozin+ Metformin SR] is indicated for the treatment of patients with type 2 diabetes mellitus.

Cardiology



Dytor E FDC [Torsemide+Eplerenone] is indicated in the Patients with Congestive Heart Failure.

Critical Care



Rizontem (Aztreonam and Avibactam powder for concentrate for solution for Infusion) is indicated in treatment of complicated Urinary Tract Infection including pyelonephritis, Hospital-acquired Pneumonia including ventilator-associated pneumonia and Complicated intra-abdominal infection

Strategic Alliances during the Quarter

Bispecific HER2 ADC



- ❑ Exclusive licensing agreement with CTTQ (SinoBiopharma Group) for TQB2102 across India, South Africa and five other emerging markets.
- ❑ Advanced bispecific HER2 ADC with a differentiated 3-in-1 mechanism and potential safety/efficacy advantages.
- ❑ Strengthens Cipla's presence in ADCs and immunotherapy, targeting HER2-low breast cancer, ~50% of breast cancer cases in India.

Pembrolizumab Biosimilar



- ❑ Exclusive U.S. licensing and supply partnership with Qilu Pharmaceutical for QL2107, a Keytruda biosimilar.
- ❑ Qilu will lead development, regulatory registration and supply, while Cipla will be responsible for U.S. commercialization.
- ❑ Strengthens Cipla's oncology-focused biosimilars portfolio and supports improved access to advanced biologic therapies, subject to regulatory approval

One India

OMNIGEL[®]

Pain Relief



Smoking
Cessation

prolyte[®]

Hydration

CIPLADINE[®]

Skin Infection



Cold and
Cough

Consumer Brands in
One India

Revenue : INR 427 Cr



Consumer Brands in
South Africa

Revenue : ZAR 463 Mn

One Africa

Cipla Actin

Respi OTC



Pain
Management

ASTHAVENT
Metered-dose inhaler

Respi OTC

CORYX

Cold and Flu

BRONCOL

Cold and
Cough


Key Business Highlights – Q2FY27



- gProventil ranked No. 1 with total market¹ share at 22% (50 million+ inhaler units supplied to the U.S. market cumulatively)
- Received U.S. FDA approval for gAdvair Diskus across all three strengths (100/50, 250/50, and 500/50 mcg), an important milestone for our U.S. respiratory business

Recent New Launches

gVentolin



Nintedanib



Dapagliflozin



Liraglutide




1. Market data as per IQVIA week ending 25th September 2026 (No. 1 rank in overall U.S. Albuterol MDI market)

ANDA & NDA Portfolio & Pipeline (As on 30th September 2026)




■ Cipla Ltd ■ PEPFAR¹ ■ Invagen ■ Partnered ANDAs/NDAs



1. PEPFAR approved ANDAs can be commercialised in US

One Africa¹ : South Africa Private Growing Faster than the Market



SA Key Highlights²

- Healthy performance across key therapies like G.U. system + Sex Hormones, Nervous System and Dermatologicals
- 10 brands with MAT market revenue > 100 Mn ZAR
- Highest number of brands in top 30 (6), top 50 (11) and top 100 (20) within generics segment
- Private business revenue of ZAR 1,294 Mn for Q2FY27

Market Segment ²	Rank	Share	Cipla Growth	Market Growth
South Africa Prescription	2	8.9%	9.9%	6.0%
South Africa OTC	3	7.7%	0.3%	3.3%
South Africa Overall	3	8.5%	6.5%	5.0%



Growth 1.3X²
Faster growth than market for private business



6 new launches
Across multiple therapies in Q2 FY27

1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Aug'26

Progress on ESG goals (India Manufacturing Operations) : Q2FY27

	Aspects	Goals FY 2029-30	Progress
Environment 	Renewable Electricity Share	80% renewable electricity share for India manufacturing	77%*
	GHG Emissions (Scope 1 & 2)	<ul style="list-style-type: none"> 30% absolute reduction (Scope 1-Energy based & Scope-2) from baseline of FY2023-24 for Global Cipla Build capacity infrastructure for green propellants used in MDI 	44%** Ongoing pilot project
	Water Neutrality	Water Neutral for India manufacturing	Achieved 2.6 times water positivity in FY26. Next Certification- Mar'27
	Zero Waste to Landfill	Maintain ZWL status for Cipla India and expand coverage for ZWL to overseas sites for USA and One Africa	CMM Certified- July'26; India Manufacturing Certification- Mar'27
Social 	AMR	One antibiotic product per Cipla India site certified as per AMR manufacturing standard	Certification for 2 Sites- Mar'27
	Occupational Health and Safety	Zero fatality in manufacturing operations	0
	DEI	Representation of women in Cipla Leadership Group at 20% or above from a baseline year of FY25	15.8%
Governance 	Responsible Procurement	Minimum 80% of critical Indian suppliers to comply with Cipla ESG framework	Preparation of supplier assessment ESG framework

Achievement

CIPLA PHARMACEUTICALS LIMITED D8, Kurkumbh has achieved **Silver Certification** under **LEED v4 BD+C Bronze Medal** for year 2026 in EcoVadis, ranking among the top 35% of globally rated companies

• * Based on normalization of IREC volumes progress YTD Aug'26 ** Decrease in the Central Electricity Authority (CEA) emission factor in FY 26-27 versus FY 23-24
 • CMM=CIPLA MEDPRO MANUFACTURING PTY LTD, South Africa

INR Cr

Particulars	Q2FY27	Q2FY26
Revenue from sale of products	7,368	7,447
Other operating income	36	142
Income from operations	7,404	7,589
Material cost	2,634	2,498
Employee benefits expense	1,475	1,315
Other expenses	1,908	1,882
Total expenses	6,016	5,695
Finance costs	17	13
Depreciation, impairment and amortisation expense	345	297
Other income	151	269
Profit before exceptional items and tax	1,177	1,854
Exceptional Items	-	-
Profit before tax	1,177	1,854
Tax expenses	321	500
Share of associate	-5	-
Profit for the period	852	1,353
Non-controlling interest	-26	2
Profit for the period attributable to shareholders	878	1,351

Note : Figures have been rounded-off

Consolidated Balance Sheet



INR Cr

Key Balance Sheet Items	Sep-26	Sep-25
Equity	35,522	33,025
Total Debt [#]	699	467
Inventory	6,778	6,160
Cash and Cash Equivalents*	10,522	10,368
Trade Receivables	6,000	6,902
Trade Payables	3,266	3,035
Net Tangible Assets	8,266	6,996
Goodwill and Intangibles	7,107	5,374

[#]Total debt includes lease liabilities and borrowings | ^{*}Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances
| Figures have been rounded-off



Cipla

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Diksha Maheshwari

Investor.Relations@cipla.com

For more information, please visit

www.cipla.com